Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Transplant Rev (Orlando). 2011 Jul;25(3):110-6. doi: 10.1016/j.trre.2010.11.002. Epub 2011 Apr 21.
The balance between effector T cells and regulatory T cells (Tregs) is central to transplant tolerance. Therefore, the impact of immunosuppressive therapies on their fate is a major determinant of long-term allograft outcome. The biologic agents are new molecules that show promise as more selective therapies with less adverse effects. Because they target mostly surface markers or costimulatory pathways of lymphocytes, it is of critical importance to evaluate their effect on both effector T cells and Tregs. The present review provides a brief summary of Tregs physiology and then discusses actual knowledge on the impact of the biologic agents on the frequency of Tregs as well as their function in vitro and in vivo in humans.
效应 T 细胞和调节性 T 细胞（Tregs）之间的平衡是移植耐受的核心。因此，免疫抑制治疗对其命运的影响是长期移植物结局的主要决定因素。生物制剂是新的分子，作为具有更少副作用的更具选择性的治疗方法具有很大的前景。由于它们主要针对淋巴细胞的表面标志物或共刺激途径，因此评估它们对效应 T 细胞和 Tregs 的影响非常重要。本综述简要总结了 Tregs 的生理学，然后讨论了生物制剂对 Tregs 频率及其在体外和体内对人类功能的影响的实际知识。
